More Intense Treatment, Worse Quality of Life in Diabetes

Share this content:
Measuring the quality of life and status of health is imperative in patients with diabetes.
Measuring the quality of life and status of health is imperative in patients with diabetes.

(HealthDay News) — Patients with diabetes report worse quality of life (QoL) with more intensified treatment, according to a study published in Diabetes Care.

Clare Bradley, PhD, from the University of London, and colleagues assessed predictors (patient characteristics, physician-reported adherence, complications, and glycosylated hemoglobin) for patient-reported outcome measures (PROMs) among 5813 patients with type 2 diabetes.

The researchers found that mean PROM scores indicated that QoL was "good." Patient-reported treatment satisfaction exceeded physicians' estimates. Worse QoL was predicted by intensifying treatments to 3 oral agents or insulin regimens (P <0.01). Use of insulin alone also predicted worse QoL (P < 0.02), as did hypoglycemia worry (P <0.007). There were no significant associations between any treatment and EuroQoL-5 Dimension visual analogue scale health status.

"The findings demonstrate the importance of measuring QoL alongside health status and other patient-reported outcomes when evaluating diabetes treatments with a view to protecting QoL and facilitating adherence and long-term glycemic control," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca and Bristol-Myers Squibb, both of which funded the trial.

Reference

Bradley C, Eschwège E, de Pablos-Velasco P, et al. Predictors of quality of life and other patient-reported outcomes in the PANORAMA multinational study of people with type 2 diabetes. Diabetes Care. 2017 Nov. doi: 
10.2337/dc16-2655

You must be a registered member of Renal and Urology News to post a comment.

Newsletter Signup